Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligilactobacillus animalis LA-1
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ligilactobacillus animalis LA-1 is a canine-derived probiotic strain isolated from the feces of healthy dogs. It has been investigated for its potential anti-obesity and metabolic regulatory effects in preclinical models, specifically in high-fat diet (HFD)-induced obese mice. The strain's mechanism of action involves the modulation of gut microbiota composition, characterized by a reduction in the Firmicutes/Bacteroidetes ratio and an enrichment of short-chain fatty acid (SCFA)-producing genera. This modulation leads to increased production of acetate, propionate, and butyrate, which in turn influences hepatic metabolic pathways, resulting in decreased levels of acetyl-CoA, triglycerides, and bile acids. Preclinical studies have shown that LA-1 supplementation significantly alleviates weight gain, hepatic lipid accumulation, and adipose tissue hypertrophy without affecting food intake.
- Other names
- L. animalis LA-1
Beyond the preview
Go deeper on Ligilactobacillus animalis LA-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ligilactobacillus animalis LA-1.